Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The drug is still associated with a lower liver cancer rate than Baraclude.
A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna
Tenofovir was associated with a lower risk of hepatocellular carcinoma, but this might be related to other factors as well.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Researchers analyzed a cohort of South Koreans taking Viread (tenofovir disoproxil fumarate) or Baraclude (entecavir) for hepatitis B.
With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.
The exception is those people with hepatitis B and liver cancer.
Treatment with Viread and Baraclude led to a decline in liver cancer in Europe but not in South Korea.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.